Literature DB >> 29428358

Central Veno-Arterial Extracorporeal Membrane Oxygenation (C-VA-ECMO) After Cardiothoracic Surgery: A Single-Center Experience.

Antonio Rubino1, Diego Costanzo2, Daniel Stanszus3, Kamen Valchanov3, David Jenkins4, Federico Sertic4, Jo-Anne Fowles5, Alain Vuylsteke3.   

Abstract

OBJECTIVES: Central veno-arterial extracorporeal membrane oxygenation (C-VA-ECMO) provides temporary cardiorespiratory support for patients in heart failure who cannot be weaned from cardiopulmonary bypass successfully. Outcomes are influenced by the reversibility of the initial insult and complications of the technique.
METHODS: The authors reviewed their single-center experience over the last 8 years to inform future practice. The study included all patients supported with C-VA-ECMO after cardiothoracic surgery between January 2008 and July 2016. The authors identified mortality risk factors using logistic regression analysis and chi-square tests.
RESULTS: One hundred and one patients were supported with C-VA-ECMO during the studied period. Weaning from ECMO was successful in 57.4% of patients, whereas 7.9% were bridged to veno-venous ECMO, 2% to peripheral veno-arterial ECMO, and 2% to biventricular ventricular assist devices. In-hospital and 1-year survival for all patients was 33.7% and 27.7%, respectively. Survival was considerably higher in transplantation patients (n = 11), at 63.6% and 54.5%, respectively. Risk factors linked to in-hospital mortality were age older than 70 years, lactate level greater than 4 mmol/L after 48 hours, and hepatic and kidney failure during ECMO support.
CONCLUSIONS: Overall one-third of patients in the cohort who the authors believe would otherwise have died from postcardiotomy cardiogenic shock survived because C-VA-ECMO was commenced after cardiac surgery. Survival is greater in transplantation patients necessitating this form of support during or immediately after surgery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac surgery; cardiogenic shock; cardiopulmonary bypass; extracorporeal membrane oxygenation; heart failure; transplantation

Mesh:

Year:  2017        PMID: 29428358     DOI: 10.1053/j.jvca.2017.12.003

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  4 in total

1.  The association between postoperative complications and prognosis in patients receiving extracorporeal membrane oxygenation in cardiac care unit.

Authors:  Liwen Liang; Liyuan Liu; Yamin Zhang; Xiaoying Fan; Ling Tao
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 2.  Structured review of post-cardiotomy extracorporeal membrane oxygenation: part 1-Adult patients.

Authors:  Roberto Lorusso; Giuseppe Maria Raffa; Khalid Alenizy; Niels Sluijpers; Maged Makhoul; Daniel Brodie; Mike McMullan; I-Wen Wang; Paolo Meani; Graeme MacLaren; Mariusz Kowalewski; Heidi Dalton; Ryan Barbaro; Xiaotong Hou; Nicholas Cavarocchi; Yih-Sharng Chen; Ravi Thiagarajan; Peta Alexander; Bahaaldin Alsoufi; Christian A Bermudez; Ashish S Shah; Jonathan Haft; David A D'Alessandro; Udo Boeken; Glenn J R Whitman
Journal:  J Heart Lung Transplant       Date:  2019-08-10       Impact factor: 10.247

3.  Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.

Authors:  Sasa Rajsic; Benedikt Treml; Dragana Jadzic; Robert Breitkopf; Christoph Oberleitner; Marina Popovic Krneta; Zoran Bukumiric
Journal:  Ann Intensive Care       Date:  2022-10-05       Impact factor: 10.318

4.  Understanding the "extracorporeal membrane oxygenation gap" in veno-arterial configuration for adult patients: Timing and causes of death.

Authors:  Maged Makhoul; Samuel Heuts; Abdulrahman Mansouri; Fabio Silvio Taccone; Amir Obeid; Belliato Mirko; Lars Mikael Broman; Maximilian Valentin Malfertheiner; Paolo Meani; Giuseppe Maria Raffa; Thijs Delnoij; Jos Maessen; Gil Bolotin; Roberto Lorusso
Journal:  Artif Organs       Date:  2021-07-06       Impact factor: 3.094

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.